Medication-Assisted Treatment of Opioid Use Disorder

2011, Vital signs: overdoses of prescription opioid pain relieversUnited States, 1999-2008., MMWR Morb Mortal Wkly Rep, 60, 1487

Bailey, 2009, The underrecognized toll of prescription opioid abuse on young children., Ann Emerg Med, 53, 419, 10.1016/j.annemergmed.2008.07.015

Zosel, 2013, Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-related Surveillance (RADARS()) System., J Am Acad Child Adolesc Psychiatry, 52, 196, 10.1016/j.jaac.2012.11.014

Valdiserri, 2014, Confronting the emerging epidemic of HCV infection among young injection drug users., Am J Public Health, 104, 816, 10.2105/AJPH.2013.301812

Volkow, 2014, Medication-assisted therapiestackling the opioid-overdose epidemic., N Engl J Med, 370, 2063, 10.1056/NEJMp1402780

Veilleux, 2010, A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction., Clin Psychol Rev, 30, 155, 10.1016/j.cpr.2009.10.006

Hill, 2012, Diagnosing and treating opioid dependence., J Fam Pract, 61, 588

Bart, 2012, Maintenance medication for opiate addiction: the foundation of recovery., J Addict Dis, 31, 207, 10.1080/10550887.2012.694598

Correia, 2006, Effects associated with double-blind omission of buprenorphinenaloxone over a 98-h period., Psychopharmacology, 189, 297, 10.1007/s00213-006-0571-4

Amass, 1994, Alternate-day dosing during buprenorphine treatment of opioid dependence., Life Sci, 54, 1215, 10.1016/0024-3205(94)00848-5

Tompkins, 2014, A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine., J Pharmacol Exp Ther, 348, 217, 10.1124/jpet.113.209478

Sarton, 2008, Naloxone reversal of opioid-induced respiratory depression with special emphasis on the partial agonistantagonist buprenorphine., Adv Exp Med Biol, 605, 486, 10.1007/978-0-387-73693-8_85

Pilgrim, 2013, A review of methadone deaths between 2001 and 2005 in Victoria, Australia., Forensic Sci Int, 226, 216, 10.1016/j.forsciint.2013.01.028

McCance-Katz, 2010, Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review., Am J Addict, 19, 4, 10.1111/j.1521-0391.2009.00005.x

Krupitsky, 2013, Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness., Addiction, 108, 1628, 10.1111/add.12208

Diaz, 2002, Regulation of mu-opioid receptors, G-protein-coupled receptor kinases and beta-arrestin 2 in the rat brain after chronic opioid receptor antagonism., Neuroscience, 112, 345, 10.1016/S0306-4522(02)00073-8

Volpe, 2011, Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs., Regul Toxicol Pharmacol, 59, 385, 10.1016/j.yrtph.2010.12.007

Yuan, 2013, Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mukappa opioid receptor dual selectivity., J Med Chem, 56, 9156, 10.1021/jm4012214

Krupitsky, 2011, Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial., Lancet, 377, 1506, 10.1016/S0140-6736(11)60358-9

Fudala, 2003, Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone., N Engl J Med, 349, 949, 10.1056/NEJMoa022164

Weiss, 2011, Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial., Arch Gen Psychiatry, 68, 1238, 10.1001/archgenpsychiatry.2011.121

Woody, 2008, Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial., JAMA, 300, 2003, 10.1001/jama.2008.574

Mattick, 2009, Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence., Cochrane Database Syst Rev, CD002209

Gibson, 2007, Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records., Drug Alcohol Rev, 26, 405, 10.1080/09595230701373834

Nunes, 2006, Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness Am J Drug Alcohol A, buse, 32, 503

Kelty, 2012, Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use., Addiction, 107, 1817, 10.1111/j.1360-0443.2012.03910.x

Larney, 2014, A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence., Drug Alcohol Rev, 33, 115, 10.1111/dar.12095

Ling, 2010, Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial., JAMA, 304, 1576, 10.1001/jama.2010.1427

Mattick, 2014, Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence., Cochrane Database Syst Rev, 2, CD002207

DeFulio, 2012, Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial., Drug Alcohol Depend, 120, 48, 10.1016/j.drugalcdep.2011.06.023

Everly, 2011, Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial., Addiction, 106, 1309, 10.1111/j.1360-0443.2011.03400.x

Thompson, 2015, Novel GPCR paradigms at the mu-opioid receptor., Br J Pharmacol, 172, 287, 10.1111/bph.12600

Williams, 2013, Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance., Pharmacol Rev, 65, 223, 10.1124/pr.112.005942

Birdsong, 2013, Increased agonist affinity at the mu-opioid receptor induced by prolonged agonist exposure., J Neurosci, 33, 4118, 10.1523/JNEUROSCI.4187-12.2013

Haerian, 2013, OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis., Pharmacogenomics, 14, 813, 10.2217/pgs.13.57

Whistler, 2012, Examining the role of mu opioid receptor endocytosis in the beneficial and side-effects of prolonged opioid use: from a symposium on new concepts in mu-opioid pharmacology., Drug Alcohol Depend, 121, 189, 10.1016/j.drugalcdep.2011.10.031

Grecksch, 2006, Development of tolerance and sensitization to different opioid agonists in rats., Psychopharmacology, 186, 177, 10.1007/s00213-006-0365-8

Hajj, 2013, Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg., Pharmacogenomics, 14, 575, 10.2217/pgs.13.13

Dennis, 2014, Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis., PLoS One, 9, e86114, 10.1371/journal.pone.0086114

Zweben, 1990, Methadone maintenance in the treatment of opioid dependence. A current perspective., West J Med, 152, 588

Hser, 2014, Treatment retention among patients randomized to buprenorphinenaloxone compared to methadone in a multi-site trial., Addiction, 109, 79, 10.1111/add.12333

Minozzi, 2013, Maintenance agonist treatments for opiate-dependent pregnant women., Cochrane Database Syst Rev, 12, CD006318

Woody, 2014, HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial., J Acquir Immune Defic Syndr, 66, 288, 10.1097/QAI.0000000000000165

Ahmadi, 2003, Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study., Eur J Clin Invest, 33, 824, 10.1046/j.1365-2362.2003.01218.x

Gowing, 2011, Oral substitution treatment of injecting opioid users for prevention of HIV infection., Cochrane Database Syst Rev, CD004145

Edelman, 2014, The impact of buprenorphinenaloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients., Drug Alcohol Depend, 139, 79, 10.1016/j.drugalcdep.2014.03.006

Otiashvili, 2013, Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavioroutcomes of a randomized trial., Drug Alcohol Depend, 133, 376, 10.1016/j.drugalcdep.2013.06.024

Meade, 2010, HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study., J Acquir Immune Defic Syndr, 55, 65, 10.1097/QAI.0b013e3181d916db

Saxon, 2013, Buprenorphinenaloxone and methadone effects on laboratory indices of liver health: a randomized trial., Drug Alcohol Depend, 128, 71, 10.1016/j.drugalcdep.2012.08.002

Hagan, 2008, Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place., Am J Epidemiol, 168, 1099, 10.1093/aje/kwn237

Pouget, 2012, Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment., Addiction, 107, 1057, 10.1111/j.1360-0443.2011.03765.x

Palmateer, 2014, Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data., J Viral Hepat, 21, 25, 10.1111/jvh.12117

Nolan, 2014, The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users., Addiction, 109, 2053, 10.1111/add.12682

Tsui, 2014, Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users., JAMA Intern Med, 174, 1974, 10.1001/jamainternmed.2014.5416

Wikner, 2014, Opioid-related mortality and filled prescriptions for buprenorphine and methadone., Drug Alcohol Rev, 33, 491, 10.1111/dar.12143

Baumblatt, 2014, High-risk use by patients prescribed opioids for pain and its role in overdose deaths., JAMA Intern Med, 174, 796, 10.1001/jamainternmed.2013.12711

Chou, 2014, Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline., J Pain, 15, 338, 10.1016/j.jpain.2014.01.495

Zlotorzynska, 2014, Timing of income assistance payment and overdose patterns at a Canadian supervised injection facility., Int J Drug Policy, 25, 736, 10.1016/j.drugpo.2014.03.014

Darke, 2014, Opioid overdose and the power of old myths: what we thought we knew, what we do know and why it matters., Drug Alcohol Rev, 33, 109, 10.1111/dar.12108

Walley, 2013, Opioid overdose prevention with intranasal naloxone among people who take methadone., J Subst Abuse Treat, 44, 241, 10.1016/j.jsat.2012.07.004

White, 1999, Mechanisms of fatal opioid overdose., Addiction, 94, 961, 10.1046/j.1360-0443.1999.9479612.x

Zedler, 2014, Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients., Pain Med, 15, 1911, 10.1111/pme.12480

Madadi, 2013, Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in Ontario, Canada., PLoS One, 8, e60600, 10.1371/journal.pone.0060600

2012, Community-based opioid overdose prevention programs providing naloxoneUnited States, 2010., MMWR Morb Mortal Wkly Rep, 61, 101

Ritter, 2002, Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose., Aust N Z J Psychiatry, 36, 224, 10.1046/j.1440-1614.2002.01012.x

Mitchell, 2012, Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection., J Stud Alcohol Drugs, 73, 991, 10.15288/jsad.2012.73.991

McNicholas, 2012, Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication., Addiction, 1, 91, 10.1111/j.1360-0443.2012.04043.x

Bogenschutz, 2010, Effects of buprenorphine and hepatitis C on liver enzymes in adolescents and young adults., J Addict Med, 4, 211, 10.1097/ADM.0b013e3181c4e27e

Fung, 2000, Evaluation of the profile of patients with QTc prolongation in spontaneous adverse event reporting over the past three decades1969-1998., Pharmacoepidemiol Drug Saf, 9, S24

Pani, 2013, QTc interval screening for cardiac risk in methadone treatment of opioid dependence., Cochrane Database Syst Rev, 6, CD008939

Lintzeris, 2007, Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients., Drug Alcohol Depend, 91, 187, 10.1016/j.drugalcdep.2007.05.019

Cohier, 2014, Respiratory effects of buprenorphinenaloxone alone and in combination with diazepam in naive and tolerant rats., Toxicol Lett, 228, 75, 10.1016/j.toxlet.2014.04.009

Lintzeris, 2006, Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients., J Clin Psychopharmacol, 26, 274, 10.1097/01.jcp.0000219050.33008.61

McCance-Katz, 2011, Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients., Drug Alcohol Depend, 118, 326, 10.1016/j.drugalcdep.2011.04.013

McCance-Katz, 2007, Interaction between buprenorphine and atazanavir or atazanavirritonavir., Drug Alcohol Depend, 91, 269, 10.1016/j.drugalcdep.2007.06.007

Saber-Tehrani, 2011, Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence., Am J Drug Alcohol Abuse, 37, 1, 10.3109/00952990.2010.540279

Jones, 2012, Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review., Addiction, 1, 5, 10.1111/j.1360-0443.2012.04035.x

Gower, 2014, The wellbeing of infants exposed to buprenorphine via breast milk at 4 weeks of age., J Hum Lact, 30, 217, 10.1177/0890334413517748

Pritham, 2013, Breastfeeding promotion for management of neonatal abstinence syndrome., J Obstet Gynecol Neonatal Nurs, 42, 517, 10.1111/1552-6909.12242

Gaalema, 2012, Differences in the profile of neonatal abstinence syndrome signs in methadone-versus buprenorphine-exposed neonates., Addiction, 1, 53, 10.1111/j.1360-0443.2012.04039.x

Salisbury, 2012, Fetal assessment before and after dosing with buprenorphine or methadone., Addiction, 1, 36, 10.1111/j.1360-0443.2012.04037.x

Coyle, 2012, Neonatal neurobehavior effects following buprenorphine versus methadone exposure., Addiction, 1, 63, 10.1111/j.1360-0443.2012.04040.x

Kaltenbach, 1984, Developmental outcome of children born to methadone maintained women: a review of longitudinal studies., Neurobehav Toxicol Teratol, 6, 271

Bell, 2009, Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment., Addiction, 104, 1193, 10.1111/j.1360-0443.2009.02627.x

Sigmon, 2012, Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice., Am J Drug Alcohol Abuse, 38, 187, 10.3109/00952990.2011.653426

Larance, 2014, The diversion and injection of a buprenorphine-naloxone soluble film formulation., Drug Alcohol Depend, 136, 21, 10.1016/j.drugalcdep.2013.12.005

Schuman-Olivier, 2013, Clinician beliefs and attitudes about buprenorphinenaloxone diversion., Am J Addict, 22, 574, 10.1111/j.1521-0391.2013.12024.x

Pedapati, 2011, Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphinenaloxone., Pediatr Crit Care Med, 12, e102, 10.1097/PCC.0b013e3181f3a118

Keen, 2001, Residential rehabilitation for drug users: a review of 13 months intake to a therapeutic community., Fam Pract, 18, 545, 10.1093/fampra/18.5.545

Kosten, 2002, The Lexington narcotic farm., Am J Psychiatry, 159, 22, 10.1176/appi.ajp.159.1.22

McHugh, 2013, Predictors of dropout from psychosocial treatment in opioid-dependent outpatients., Am J Addict, 22, 18, 10.1111/j.1521-0391.2013.00317.x

Warden, 2012, Predictors of attrition with buprenorphinenaloxone treatment in opioid dependent youth., Addict Behav, 37, 1046, 10.1016/j.addbeh.2012.04.011

Mayet, 2005, Psychosocial treatment for opiate abuse and dependence., Cochrane Database Syst Rev, CD004330

Masson, 2004, Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification., Addiction, 99, 718, 10.1111/j.1360-0443.2004.00728.x

Magura, 2001, Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored., Mt Sinai J Med, 68, 62

Soyka, 2014, Opioids and traffic safetyfocus on buprenorphine., Pharmacopsychiatry, 47, 7

Rapeli, 2011, Cognitive functioning in opioid-dependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates., BMC Clin Pharmacol, 11, 13, 10.1186/1472-6904-11-13

Garbutt, 2005, Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial., JAMA, 293, 1617, 10.1001/jama.293.13.1617

OMalley, 2007, Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment., J Clin Psychopharmacol, 27, 507, 10.1097/jcp.0b013e31814ce50d

Heinrich, 2014, Adoption and diffusion of evidence-based addiction medications in substance abuse treatment., Health Serv Res, 49, 127, 10.1111/1475-6773.12093

Lang, 2013, Qualitative investigation of barriers to accessing care by people who inject drugs in Saskatoon, Canada: perspectives of service providers., Subst Abuse Treat Prev Policy, 8, 8, 10.1186/1747-597X-8-35

Fiellin, 2001, Methadone maintenance in primary care: a randomized controlled trial., JAMA, 286, 1724, 10.1001/jama.286.14.1724

Roux, 2012, Methadone induction in primary care (ANRS-Methaville): a phase III randomized intervention trial., BMC Public Health, 12, 488, 10.1186/1471-2458-12-488

Kahan, 2009, Short-term outcomes in patients attending a primary care-based addiction shared care program., Can Fam Physician, 55, 1108

Debelak, 2013, Buprenorphine naloxone in the treatment of opioid dependence during pregnancyinitial patient care and outcome data., Am J Addict, 22, 252, 10.1111/j.1521-0391.2012.12005.x

Neumann, 2013, A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction., J Addict Dis, 32, 68, 10.1080/10550887.2012.759872

Shi, 2009, Time-dependent neuroendocrine alterations and drug craving during the first month of abstinence in heroin addicts., Am J Drug Alcohol Abuse, 35, 267, 10.1080/00952990902933878

Li, 2009, Circadian alteration in neurobiology during 30 days of abstinence in heroin users., Biol Psychiatry, 65, 905, 10.1016/j.biopsych.2008.11.025

Marsch, 2005, Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial., Arch Gen Psychiatry, 62, 1157, 10.1001/archpsyc.62.10.1157

Chartoff, 2014, Its MORe exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system., Front Pharmacol, 5, 116, 10.3389/fphar.2014.00116

Sanders, 2013, Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure., Exp Clin Psychopharmacol, 21, 294, 10.1037/a0033724

Bisaga, 2014, A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence., J Subst Abuse Treat, 46, 546, 10.1016/j.jsat.2014.01.005

Bisaga, 2011, A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence., Drug Alcohol Depend, 119, e23, 10.1016/j.drugalcdep.2011.05.019

Tabatabai, 2014, Phytotherapy of opioid dependence and withdrawal syndrome: a review., Phytother Res, 28, 811, 10.1002/ptr.5073

Gao, 2014, An-jun-ning, a traditional herbal formula, attenuates spontaneous withdrawal symptoms via modulation of the dopamine system in morphine-dependent rats., BMC Complement Altern Med, 14, 308, 10.1186/1472-6882-14-308